Categories

Tag: Uncategorized

POLICY: Kinsley–Good grief! (with UPDATE)

Supposed voice of liberal moderation Michael Kinsely is out with a Washington Post op-ed called Before We Go ‘Single Payer’ which is just staggering. I thought Arnold Kling was bad in his misunderstandings, but I apologize to the libertarians on this one. Kinsley’s piece just doesn’t make sense, which indicates to me that he doesn’t understand what he’s talking about.

He accuses Krugman and Wells of ducking the rationing issue — they don’t. Instead they say it can be delayed by cutting out some administrative costs, but it will come in the end. You may not buy that argument, but it is a proven fact that admin costs are lower in single payer nations than they are here. Check the CMS cost data if you don’t believe me.

But then he wonders off into absurdity.

But anyone is insurable at some price — a price that reflects the cost he or she is likely to impose on the insurer. Adverse selection is only a problem to the extent that insurance is not really insurance but rather a subsidy.

Frankly I have no idea what he’s talking about with this “subsidy” stuff. If he means that some people pay more in premiums than they receive in benefits and some pay less, then that’s what insurance is. But I have a simple way of correcting his notion that everyone is insurable at a price. Let’s give Kinsely a pre-existing condition, and send him out into the individual market. He’ll change his tune faster than Mark Pauly wold under the same circumstances.

And then he seems to have missed the whole concept of the debate on the political left between the Enthovenistas/voucher crowd and the single payers. And most importantly that no one seriously thinks Americans won’t be allowed to trade up to a better class of waiting room with their own money.

The problem is putting in a floor for everyone, not getting rid of the ceiling — that’ll come naturally once everyone’s in the same system.

Nowhere does he mention the one thing that is necessary for fixing health care — the imposition of some type of mandatory universal insurance system. Something that everyone in the voucher v single payer argument realizes is essential. And however it happens that is not “incremental change”.

(Trap, you can use this as a thread to beat up on Kinsely, Krugman me et al)

UPDATE: Meanwhile a (gasp) Republican, although not one in the good graces of the loonies running the country any more, has some ideas that are at least getting at (some of) the problem and mention the "mandatory" word. Here’s what Paul O’Neill said:

Mr. O’Neill has long argued that addressing health care with tax
incentives is an inadequate approach. "When they’re talking about tax credits,
they’re talking about our money, not their money," he said in a phone interview
last night. "When you use tax credits and deductions, unless they are
refundable, … they’re very inequitable, because the value of the credit or
deduction depends on the level of income or wealth accumulation an individual
has."Mr. O’Neill said Congress should pass a law requiring all Americans
who make more than $30,000 a year to purchase catastrophic health care coverage
for themselves and their families, with fewer deductibles and co-insurance
payments. The government would then use general revenue funds to purchase health
insurance coverage for lower-income people, he said.

POLICY/QUALITY: The intellectual backdrop has been created for P4P

Here’s my FierceHealthcare editorial

Last week a study from Wennberg’s Dartmouth group showed that there were vast variations in the amount of "physician resources" used to produce similar care outcomes, in that case in intensive care settings. This week a RAND study followed up on data released in their much quoted 2003 study which showed that patients receive the correct care from their providers only a little over 50% of the time. This new study showed that there was little to choose between the care meted out to richer, better insured, whiter people and that given to poorer, less well insured minorities. So it appears that unlike in the rest of American life, money can’t buy you better quality. And given the amount of money being spent on health care in America, that’s not a satisfactory outcome.

Putting these two studies together shows that there will be much more concentration in the resources being used and the process and outcomes of care, and most importantly, that the intellectual argument has been created for providers to be paid for quality, performance and by extension cost-efficiency. This will not be an easy change for the system to adopt, and it looks as if it may be the major story of the next decade.

POLICY: China and American health care

I was reading an article about about political infighting in the Chinese Communist Party — a decidedly non-THCB topic — called A Sharp Debate Erupts in China Over Ideologies. (Traditionally the CCP has been like Republicans, all on message with no internal dissent. Apparently they’re becoming Democrats).

Anyway this one quote grabbed me:

In a subsequent interview with Business Watch, a state-run magazine, Mr. Liu said, "If you establish a market economy in a place like China, where the rule of law is imperfect, if you do not emphasize the socialist spirit of fairness and social responsibility, then the market economy you establish is going to be an elitist market economy."

Now does that remind those of you looking at the US health care system, and in particular our basically unregulated and self-serving insurance system, of anything in particular? I thought so.

(And don’t come after me about how our insurance system is already regulated enough, or I’ll set Jonathan Cohn on you….)

 

THCB: Any budding reviewers out there?

Dr. Robert McKersie has asked me to review his book In the Foothills of Medicine. Here’s what his web site says about it.

In the Foothills of Medicine shares one doctor’s intriguing true story from the front lines of medicine. Dr. Robert McKersie writes vividly and passionately about the patients whom he saw, touched, and thought about during his intense inner city internship in family medicine and medical treks to remote villages in Nepal.

I am so far behind on so many levels that I can’t commit to spending the time to read and write about this book, but one of you brave THCB readers might. If you do, I’ll publish the review on THCB.  So let me know by email and I’ll get it sorted out.

POLICY/INDUSTRY: HSC on 10 years of change

Whe I was first figuring out the private sector in health care about 10-12 years ago while Hillary was trying and failing to get reform done, I heard a gazillion people, usually in the strategy or policy dividions of big plans and drug companies tell me that we didn’t need government reform because the market was going to sort it all out itself. And ten years after we got the market reform that meant we didn’t need governmnet reform. What happened?

"In a decade that saw the rapid rise and hard fall of tightly managed care, there was plenty of change but little progress in solving the cost, access and quality problems in the health care system," says Paul Ginsburg in the release about HSC’s 10 year retrospective.

 

You can read the full report here. It’s taken me ten years to figure out what went wrong. Let’s not have that happen again next time, eh.

PHARMA/POLICY: In this game of monopoly drugs the market is working, oh yes

So the new maker old off-patent drug that is needed badly but only by a few people, and for some reason isn’t in the Part D or most other private formularies “notices” that it has a monopoly. So what does it do?  It puts the price up nearly ten fold . (The drug is called Mustargen and the company is called Ovation Pharmaceuticals). And of course this behavior is matched by other companies that have monopolies bestowed by patents.

Presumably if the market price is that high on the non-patented drug some smart Indian generic will start making it and bring the price down, but that’ll take a little while. And in the meantime 5,000 patients are getting screwed to the wall.

We should have a rational debate about whether there ought to be coverage for certain drugs (and in the UK for instance there is such a debate).  But if there’s an egregious monopoly or market-distortion like this, then we know the solution, and it’s called monopsony — or, if you like, price-fixing. Of course this nation’s government doesn’t like to intervene in these types of cases even when it means a bunch of crooks steal blindly from a whole state and help push its economy (and by consequence that of the whole nation) into recession. And I suspect the people who need this drug view Ovation Pharma as Enron wearing lab coats.

But eventually if Pharma (both big and small) continues to abuse its monopoly power, there will be a predictable response. You can argue that making hay while the sun shines is Pharma’s best financial course (if not exactly its best ethical one), but I suspect that whoever sits in the C suites in New Jersey (and South San Francisco) and has to pick up the pieces under the next Democratic Administration may wish that a little restraint had been shown while that sun was shining.

PHARMA/QUALITY: New York Times discovers compliance

Says here, compliance with drug regimens is a big problem. (Adopt Harry Shearer voice with hard “en” sound in “knew”)”

Who knew? Who knew?

And McKesson, plus a boat load of other DM, PBM and pharma-related companies (like Pfizer Health Solutions) are bugging patients to take their pills, and increasing pharma company profits into the bargain. And even after digging up David Sobel, John Abramson & Jerry Avorn, the NYT can’t find too much bad to be said about these programs — even though pharma companies are paying for them. Everyone agrees compliance is good, and getting patients to take their pills is hard work.

But I didn’t notice them referring to any compliance programs for generics. Funny that.

White House Letter; An Outspoken Conservative Loses His Place at the Table – The Archive – The New York Times

White House Letter; An Outspoken Conservative Loses His Place at the Table – The Archive – The New York Times

Mr. Bartlett, 54, the author of a syndicated newspaper column and articles in academic journals, was dismissed in October as a senior fellow at the National Center for Policy Analysis, a research group based in Dallas. In the interview, Mr. Bartlett said he had been fired because his increasingly critical comments about Mr. Bush, in his column, in his book and in other publications, had hampered the ability of the research institution to raise money among Republican donors.He also provided a copy of an e-mail message that he said was sent to him in August 2004 by Jeanette Goodman, the vice president of the research institution. ”100K is off the table if you do another ‘dump Cheney’ column and 65K donor is having a rebuttal done, in a national magazine, to your attack on the fair tax people so that 65K may be gone also,” Ms. Goodman wrote about one of Mr. Bartlett’s columns about the vice president. ”Do you have any ideas on where I could raise that amount quickly?”John C. Goodman, the president of the organization and Ms. Goodman’s husband, said in a telephone interview over the weekend that he did not know what his wife had said to Mr. Bartlett and that he did not want to say whether Mr. Bartlett ”did or didn’t hurt fund-raising.” But Mr. Goodman added, ”That’s not why he was fired.”

assetto corsa mods